|
EP3093294A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Dll3 modulators and methods of use
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス， インコーポレイテッド |
新規ｓｅｚ６モジュレーターおよび使用方法
|
|
WO2015031698A1
(en)
*
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
|
|
MA41645A
(fr)
*
|
2015-03-04 |
2018-01-09 |
Abbvie Stemcentrx Llc |
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506388D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506399D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506407D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506393D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506394D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506405D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
JP2018524313A
(ja)
*
|
2015-06-23 |
2018-08-30 |
バイエル ファーマ アクチエンゲゼルシャフト |
キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｂ７ｈ３抗体との抗体薬物複合体
|
|
JP2018529656A
(ja)
*
|
2015-08-20 |
2018-10-11 |
アッヴィ・ステムセントルクス・エル・エル・シー |
抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法
|
|
GB201602363D0
(en)
*
|
2016-02-10 |
2016-03-23 |
Adc Therapeutics Sa And Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
CN109071666B
(zh)
|
2016-03-01 |
2022-06-28 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
人脊髓灰质炎病毒受体(pvr)特异性抗体
|
|
CA3024723A1
(en)
|
2016-05-20 |
2017-11-23 |
Robert B. Dubridge |
Single domain serum albumin binding protein
|
|
MX2018016330A
(es)
|
2016-06-27 |
2020-02-17 |
Univ California |
Combinaciones para tratamiento del cáncer.
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
UA125198C2
(uk)
|
2017-02-08 |
2022-01-26 |
Ейдісі Терапьютікс Са |
Кон'югати піролобензодіазепін-антитіло
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SI3612537T1
(sl)
|
2017-04-18 |
2022-10-28 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
JP7145891B2
(ja)
|
2017-06-14 |
2022-10-03 |
アーデーセー セラピューティクス ソシエテ アノニム |
抗ｃｄ１９ ａｄｃを投与するための投与レジメ
|
|
US20210393794A1
(en)
*
|
2017-06-20 |
2021-12-23 |
Sichuan Baili Pharm Co.Ltd |
Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
|
|
BR112020003003A2
(pt)
|
2017-08-18 |
2020-08-11 |
Medimmune Limited |
conjugados de pirrolobenzodiazepina
|
|
CN117003875A
(zh)
|
2017-09-29 |
2023-11-07 |
第一三共株式会社 |
抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
CN111542344B
(zh)
*
|
2017-10-23 |
2025-07-04 |
马布林克生物科学公司 |
包含单分子量聚肌氨酸的配体-药物-缀合物
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
BR112020021280A2
(pt)
*
|
2018-05-08 |
2021-01-26 |
Phanes Therapeutics, Inc. |
anticorpos anti-dll3 e usos dos mesmos
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
AU2019316103B2
(en)
|
2018-08-02 |
2026-02-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US20210330802A1
(en)
*
|
2018-10-10 |
2021-10-28 |
Takeda Pharmaceutical Company Limited |
Method for producing antibody-drug conjugate
|
|
EP3882349A4
(en)
|
2018-11-14 |
2023-04-05 |
Daiichi Sankyo Company, Limited |
(ANTI-CDH6 ANTIBODY)-(PYRROLOBENZODIAZEPINE DERIVATIVE) CONJUGATE
|
|
MX2021010477A
(es)
|
2019-03-15 |
2021-10-01 |
Medimmune Ltd |
Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
|
|
SG11202109860VA
(en)
|
2019-03-25 |
2021-10-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
TWI856078B
(zh)
|
2019-03-25 |
2024-09-21 |
日商第一三共股份有限公司 |
抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
|
|
BR112021017350A2
(pt)
|
2019-03-27 |
2021-11-16 |
Daiichi Sankyo Co Ltd |
Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
AU2020299382A1
(en)
*
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
|
JP7754506B2
(ja)
|
2019-10-08 |
2025-10-15 |
ネクチン セラピューティクス エルティーディー． |
ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
|
|
US20230113823A1
(en)
*
|
2020-01-31 |
2023-04-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
AU2021338014A1
(en)
|
2020-09-02 |
2023-03-09 |
Daiichi Sankyo Company, Limited |
Novel endo-β-N-acetylglucosaminidase
|
|
TW202237135A
(zh)
|
2021-01-13 |
2022-10-01 |
紀念斯隆凱特琳癌症中心 |
抗體-吡咯并苯并二氮呯衍生物結合物
|
|
JP2024525608A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
CA3226938A1
(en)
*
|
2021-07-30 |
2023-02-02 |
Qingsong GUO |
Anti-dll3 antibody and preparation method therefor, drug conjugate and application thereof
|
|
CA3231586A1
(en)
*
|
2021-09-17 |
2023-03-23 |
Yunying CHEN |
D3-binding molecules and uses thereof
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
|
EP4454662A4
(en)
*
|
2021-12-23 |
2025-04-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY
|
|
EP4477674A1
(en)
|
2022-02-09 |
2024-12-18 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
JPWO2023167238A1
(enExample)
|
2022-03-02 |
2023-09-07 |
|
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4534101A1
(en)
|
2023-10-02 |
2025-04-09 |
Eli Lilly and Company |
Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
|
|
WO2025190281A1
(en)
*
|
2024-03-11 |
2025-09-18 |
Lepu Biopharma Co., Ltd. |
Anti-dll3 antibodies and uses thereof
|
|
CN119119255B
(zh)
*
|
2024-09-20 |
2026-03-03 |
广东省生物技术研究院(广东省实验动物监测中心) |
一种猪急性腹泻综合征冠状病毒的刺突蛋白抗原表位肽及其单克隆抗体与应用
|